CVS Health AI Stock Analysis
Want to see CVS full AI Analyst Report?
CVS Health (CVS) AI Stock Analysis
CVS Health
(NYSE:CVS)
CVS scores solidly overall, led by improving financial momentum and strong cash generation (including raised cash flow guidance) plus an attractive valuation (low P/E and ~3.3% dividend). These positives are tempered by weak technicals (price below major moving averages with negative MACD) and ongoing fundamental constraints from thin margins and a still-meaningful debt load.
CVS Health Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down sales across different business units, revealing which areas contribute most to growth and where the company might face challenges or opportunities.
Health Care Benefits and Health Services are clearly the engines of growth and margin recovery—Aetna’s improving MBR and Caremark’s specialty mix and purchasing gains helped management raise guidance and cash‑flow targets—while Pharmacy and Consumer posts steadier, volume‑driven gains but remains exposed to reimbursement and 340B/regulatory pressure. Growing negative intersegment eliminations are increasingly subtracting from consolidated revenue, so prioritize operating income and cash‑flow momentum (where management raised targets) over headline revenue, given 340B uncertainty and expected Caremark membership shifts into 2027.
CVS Health (CVS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $113.35B
- Dividend Yield
- 3.00%
- Average Volume (3M)
- 9.01M
- Price to Earnings (P/E)
- 10.2
- Beta (1Y)
- 0.54
- Revenue Growth
- 6.77%
- EPS Growth
- 2114.64%
- Country
- US
- Employees
- 259,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Plans
CVS Health Business Overview & Revenue Model
Company Description
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Hea...
How the Company Makes Money
CVS Health primarily makes money by generating revenue across three major operating segments—Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness—each with distinct but complementary revenue models. 1) Health Care Benefits (primari...
CVS Health Earnings Call Summary
The call was strongly positive. CVS Health reported broad-based third-quarter earnings growth, raised 2026 revenue, adjusted EPS, operating income and cash flow guidance, achieved its leverage goal ahead of schedule and expects to resume share repurchases. Management also presented improving Medicare performance, continued pharmacy growth and a favorable longer-term outlook. The principal challenges were elevated medical cost trends, expected 2027 pressure from 340B and lower Caremark membership, and costs associated with the planned separation, but management characterized these items as manageable and described 2027 as a trough year for Health Services.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full-year 2026, CVS Health raised adjusted earnings per share guidance to at least $8.20 from the prior range of $7.90 to $8.10, expects total revenues of at least $420 billion, Health Care Benefits adjusted operating income of at least $5.4 billion, medical benefit ratio in the lower half of our previously discussed range of 89.75% plus or minus 25-basis-points, Pharmacy and Consumer Wellness adjusted operating income of $6.5 billion, and enterprise adjusted operating income of at least $17.05 billion; cash flow from operations is expected to be at least $15.5 billion, more than $5.5 billion above the initial outlook, while 2027 Health Services adjusted operating income is expected to be at least $7 billion, Pharmacy and Consumer Wellness adjusted operating income is expected to grow low single digits off our current 2026 guidance of $6.5 billion, adjusted EPS is expected to be at least $8.65, reflecting approximately 13% growth off an adjusted 2026 baseline, and the company now believes it will be in the high end of our mid-teens adjusted EPS CAGR through 2028.
CVS Health Financial Statement Overview
Summary
Fundamentals are improving but still constrained by profitability and leverage. TTM revenue growth is very strong (+133%) and earnings rebounded sharply versus 2025, while cash generation is a clear positive (TTM operating cash flow ~$18.7B; free cash flow ~$15.6B, +32%). Offsetting these strengths, margins remain thin (net ~1.2%, operating ~2.1%) and debt remains sizable (~$75.3B) despite improving leverage (debt-to-equity ~1.0).
Income Statement
62PositiveBalance Sheet
58NeutralCash Flow
71Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 420.61B | 402.07B | 372.81B | 357.78B | 322.47B | 292.11B |
| Gross Profit | 59.84B | 55.36B | 51.40B | 54.43B | 54.50B | 52.12B |
| EBITDA | 19.70B | 9.86B | 13.68B | 18.20B | 12.35B | 17.53B |
| Net Income | 11.05B | 1.77B | 4.61B | 8.34B | 4.31B | 8.00B |
Balance Sheet | ||||||
| Total Assets | 258.07B | 253.54B | 253.22B | 249.73B | 228.28B | 233.00B |
| Cash, Cash Equivalents and Short-Term Investments | 14.89B | 10.60B | 10.99B | 11.46B | 15.72B | 12.53B |
| Total Debt | 75.30B | 79.95B | 82.92B | 79.39B | 70.73B | 76.00B |
| Total Liabilities | 177.39B | 178.16B | 177.49B | 173.09B | 156.51B | 157.62B |
| Stockholders Equity | 80.50B | 75.21B | 75.56B | 76.46B | 71.47B | 75.08B |
Cash Flow | ||||||
| Free Cash Flow | 15.57B | 7.81B | 6.33B | 10.39B | 13.45B | 15.74B |
| Operating Cash Flow | 18.71B | 10.64B | 9.11B | 13.43B | 16.18B | 18.27B |
| Investing Cash Flow | -7.54B | -5.87B | -7.61B | -20.89B | -5.05B | -5.26B |
| Financing Cash Flow | -8.57B | -4.94B | -1.14B | 2.68B | -10.52B | -11.36B |
CVS Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVS, the sentiment is Neutral. The current price of 88.59 is below the 20-day moving average (MA) of 89.28, below the 50-day MA of 89.09, and above the 200-day MA of 88.17, indicating a neutral trend. The MACD of -0.46 indicates Negative momentum. The RSI at 49.68 is Neutral, neither overbought nor oversold. The STOCH value of 84.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVS.
CVS Health Risk Analysis
CVS Health disclosed 40 risk factors in its most recent earnings report. CVS Health reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
2 New RisksCVS Health Peers Comparison
Overall Rating
ELV76Outperform
CI75Outperform
CNC66Neutral
CVS65Neutral
UNH62Neutral
HUM58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $96.42B | 18.97 | 11.59% | 1.54% | 3.60% | -4.06% | |
| 75Outperform | $79.09B | 13.18 | 14.10% | 2.06% | 6.79% | -0.38% | |
| 66Neutral | $37.02B | 25.26 | 6.78% | ― | 9.71% | ― | |
| 65Neutral | $113.35B | 10.21 | 14.13% | 3.00% | 6.77% | 2114.64% | |
| 62Neutral | $369.18B | 23.39 | 16.35% | 2.20% | 3.33% | -8.75% | |
| 58Neutral | $55.40B | 44.41 | 6.70% | 0.77% | 22.02% | -3.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CVS | CVS Health Corp | 88.59 | 14.32 | 19.28% | |
| CNC | Centene | 74.77 | 38.82 | 107.98% | |
| CI | Cigna | 300.16 | 34.20 | 12.86% | |
| HUM | Humana | 461.25 | 235.30 | 104.14% | |
| UNH | Unitedhealth Group Inc. | 412.02 | 110.95 | 36.85% | |
| ELV | Elevance Health, Inc. | 446.28 | 136.08 | 43.87% |
CVS Health Corporate Events
CVS Health Announces Plan to Separate Into Two Companies
NeutralOn November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies. One would combine Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, while CVS Pharmacy would comprise about 9...
CVS Health refreshes board to drive tech-focused transformation
PositiveCVS Health announced board changes in August 2026, marking another step in its evolution toward a more technology-focused health solutions model. On August 13, 2026, director Larry M. Robbins resigned after two years on the board, with the company em...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
